Plasma Oxytocin Changes in Response to Music Modified by Sonic Augmentation Technology

NCT ID: NCT07276152

Last Updated: 2025-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-31

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigator aim to investigate wheather music modified by sonic augmentation technology can produce increasing oxytocin levels with minimal to no side effects in a highly standardized setting

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sonic Augmentation Technology

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Arginine Vasopressin Deficiency oxytocin diabetes insipidus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Part 1 is a double-blinded, randomized and cross-over proof-ofconcept trial Part 2 is an open-labeled single arm pilot study
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sonic augmentation technology (SAT) - placebo music

Participants will listen to music enhanced with SAT in their first study visit. After a washout-phase of at least 20 hours they will come to a second study visit and they will listen to placebo music

Group Type EXPERIMENTAL

sonic augmentation technology

Intervention Type OTHER

Participants/ patients listen to music enhanced with sonic aumentation technology

placebo music- sonic augmentation technology (SAT) music

Participants will listen to placebo in their first study visit. After a washout-phase of at least 20 hours they will come to a second study visit and they will listen to music enhanced with SAT

Group Type EXPERIMENTAL

sonic augmentation technology

Intervention Type OTHER

Participants/ patients listen to music enhanced with sonic aumentation technology

Sonic augmentation technology (SAT) in patients

Patients have one study visit listening to SAT

Group Type EXPERIMENTAL

sonic augmentation technology

Intervention Type OTHER

Participants/ patients listen to music enhanced with sonic aumentation technology

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sonic augmentation technology

Participants/ patients listen to music enhanced with sonic aumentation technology

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult healthy controls
* No medication, except hormonal contraception


* Confirmed diagnosis of AVP-Deficiency
* Age ≥ 18 years

Exclusion Criteria

* Participation in a trial with investigational drugs within 30 days
* Illicit substance use (except for cannabis) more than 10 times in lifetime or any time within the previous two months
* Consumption of alcoholic beverages \>15 drinks/week
* Tobacco smoking \>10 cigarettes/day
* Current or previous major psychiatric disorder (e.g., major depression, schizophrenia spectrum disorder)
* Psychotic disorder in first-degree relatives
* Pregnancy and breastfeeding

Part 2:


* Participation in a trial with investigational drugs within 30 days
* Illicit substance use (except for cannabis) more than 10 times in lifetime or any time within the previous two months
* Consumption of alcoholic beverages \>15 drinks/week
* Tobacco smoking \>10 cigarettes/day
* Current or previous major psychiatric disorder (e.g., major depression, schizophrenia spectrum disorder)
* Psychotic disorder in first-degree relatives
* Pregnancy and breastfeeding
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Basel, Switzerland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mirjam Christ-Crain, Prof.

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Basel, Switzerland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Basel

Basel, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mirjam Christ-Crain, Prof.

Role: CONTACT

Phone: +41 61 265 25 25

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mirjam Christ-Crain, Prof.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-01817, kt25christcrain6

Identifier Type: -

Identifier Source: org_study_id